Drug Profile
XD 001
Alternative Names: XD-001Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Cancer in China (unspecified route)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Cancer in China
- 07 May 2015 Preclinical trials in Cancer in China (unspecified route)